Nanoform Management Presentation - Online presentation and conference call
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Nanoform Management Presentation Online presentation and conference call August 26th - 2021, 15.00 Helsinki time Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier- segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch. For more information please visit http://www.nanoform.com
Disclaimer
Forward-Looking Statements
This presentation may contain forward-looking statements, including, without limitation, statements regarding Nanoform’s
strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any
forward-looking statements in this presentation are based on management’s current expectations and beliefs and are
subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking statements contained in this presentation, including,
without limitation, any related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and
anticipated timelines, competition from other companies, and other risks specified in Nanoform’s prospectus published (on
May 22, 2020) in connection with Nanoform’s initial public offering (the “Prospectus”) under “Risk Factors” and in our other
filings or documents furnished to the Finnish Financial Supervisory Authority in connection with the Prospectus. Nanoform
cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are
made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in
expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the
likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking
statements contained in this presentation represent Nanoform’s views only as of the date hereof and should not be relied
upon as representing its views as of any subsequent date.
2
Short introduction to Nanoform
3
Nanoform in a Snapshot
Nanoform Platform Technology
The Share
➢ Global experts in Bulk
nanotechnology and ➢ CESS® technology for small
➢ Listed June 4th, 2020 on drug particle engineering molecules (chemical
Nasdaq First North Premier API compounds) discovered in
Growth Market in Helsinki 2012
and Stockholm ➢ ~110 employees and growing, 37 with
PhD degree and 25 nationalities
➢ Technology for large molecules
➢ Tickers: NANOFH and (biological compounds)
NANOFS ➢ Headquartered in Finland with additional launched in 2020
senior staff and board members in
Denmark, Portugal, Sweden, UK and US
➢ Significant Nordic, European
and US institutional ➢ Nanoform’s clinical results
ownership ➢ >3000m2 manufacturing site in Helsinki confirm value proposition to
for nanoforming API’s the pharma industry
➢ All press releases:
https://nanoform.com/en/s ➢ Strong balance sheet, EUR 88m in cash,
ection/media/press- no debt
releases/
API = Active Pharmaceutical Ingredient
CESS® = Controlled Expansion of Supercritical Solutions 4
GMP = Good Manufacturing Practice
Low bioavailability is the key issue
Poor bioavailability and low efficacy most common reasons for drug failure Majority of new drugs suffer from poor solubility
Solubility
Reasons for drug failure in pre-clinical trials (share of molecules)
High Low
45%
40%
35% Class I1 Class II1
On market: 35% On market: 30%
High
30%
New drugs: 5-10% New drugs: 60-70%
25%
70-90%
Permeability
20% 39%
of new drugs
15% 30% are poorly
soluble
10%
Class III1 Class IV1
11%
Low
5% 10% 10% On market: 25% On market: 10%
New drugs: 5-10% New drugs: 10-20%
0%
Poor Low efficacy High toxicity Adverse effects Others
bioavailability
➢ Nanoform can enhance the pharma industry output by targeting poorly soluble drugs
Source: GlobalData 2009, Cutting Edge Water-based Nanotechnology in Drug Development (Reasons for drug
failure); Nikolakakis & Partheniadis (2017), Self-Emulsifying Granules and Pellets: Composition and Formation
Mechanisms for Instant or Controlled Release (Share of poorly soluble drugs)
5
1) Classification of drug substance according to Biopharmaceutics Classification System (BCS)
Nanoform is here to fill the gap
The solution to low bioavailability is to decrease the particle size of the
Active Pharmaceutical Ingredient (API)
Giving
unsuccessful
drug candidates Improving Enabling new
a second chance existing drugs drugs
>58 000 failed >5 800 >18 000 drugs in
drugs in the last existing drugs* development*
40 years*
Nanoform’s CESS® is the only technology that can manufacture nanoparticles
without solvents, excipients and complex production processes
API = Active Pharmaceutical Ingredient
CESS® = Controlled Expansion of Supercritical Solutions 6
*Source: Nanoform and Pharmaprojects® | Informa, 2021
Particle size is key
Smaller particle size can improve a drug’s bioavailability
Pre-nanoforming Post-nanoforming
➢ Smaller particles have a larger surface area
➢ Larger surface area of particles enables better bioavailability of a
drug
➢ The surface area increases 30 fold from a 10 micron1 sized particle ➢ Improved bioavailability implies better absorption of a drug by the
once the particle size is reduced to 100nm body’s circular system
➢ Reduction of particle size down to 50nm increases the surface area by ➢ CESS® can produce API with large surface areas which can
1,000 fold significantly improve the bioavailability of drugs
➢ CESS® produced nanoparticles have a larger surface area and as such improved bioavailability
Source: Company information
7
1) 1 micron = 1,000nm
Small is powerful®
CESS® = Controlled Expansion of Supercritical Solutions 8
Nanoforming a potential game-changer in Biologics too
Drug
Improving Tailored
loading
delivery release
capacity in
route profiles
formulations
Implementing
Enabling new lighter
Improving
drug infrastructure
uptake combinations for drug
logistics
Source: Company information 9
Nanoform the stars that will shine
the brightest with…
➢ Enables in silico experiments in large
quantities, creating fast predictions of
which molecules should be nanoformed
➢ Helps pharma partners to pick suitable
drug candidates for further development
from their large libraries
➢ Applicability in drug discovery,
development and in lifecycle management
for existing marketed drugs
10Logarithmic growth
1 Million
evaluations
per week
Expert knowledge +
1000
Artificial Intelligence
evaluations ↓
per week
Growth
Starmap2.0
launched
10
evaluations
per week
2020 2021 2025
11Market overview
12Global pharma market projected to reach USD 1.6tn by 2025
Global medicine spending 2010-2025E (USDtn) Global prescription drug sales from top 100 products (USDbn)
1.8
$1.6tn
400
1.6
357
1.4 350
306
1.2 300
$0.9tn 262
1.0 250
0.8 200
0.6 150
0.4 100
0.2 50
0.0 0
2010 2018 2024E
➢ Significant market potential in improving the properties of existing drugs
Source: IQVIA Institute for Human Data Science; EvaluatePharma 13The structural pharma R&D problem
Less than 50 drugs approved in the US annually on average… …while the global pharma industry R&D expenditure exceeds $180B
Annual number of novel drug approvals by FDA 2010-2020 Global pharmaceutical R&D spending 2010-2026E (USDbn)
Chemical Biologics
60 250
233
227
221
211
50 17 202
195
200 188
181 186
10 20 168
40 12 160
12
145 150
6 11 150 137 136 138
129
30
6 2
100
20 42
6 7 38
33 33 34 33
30
24 25 50
10
15 15
0 0
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
➢ A game changer in particle design is needed to improve R&D yield
Source: U.S. Food and Drug Administration (FDA); IQVIA Institute for Human Data Science 14Global drug R&D pipeline size and growth
18,582
drugs
20,000
2016-2021 growth
36% (6.3% p.a.)
17,737
17,500
16,181
15,267
2011-2016 growth 14,872
15,000 41% (7.1% p.a.)
Drug count
13,713
12,300
12,500 2006-2011 growth
31% (5.6% p.a.) 11,307
10,452 10,479
2001-2006 growth 9,737 9,713
10,000 9,605
24% (4.3% p.a.) 9,217
7,737
7,360 7,406
7,500 6,994
6,416
5,995 6,198
5,000
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Year
Source: Pharmaprojects® | Informa, 2021 15Global number of companies with active pipelines
5,099
6,000 companies
2016-2021 growth
38% (6.7% p.a.)
5,000 4,816
4,323
Company count
4,134
2011-2016 growth 4,003
4,000 51% (9.1% p.a.)
3,687
3,286
2006-2011 growth
46% (7.9% p.a.) 2,984
3,000
2,705 2,745
2001-2006 growth
2,387
36% (4% p.a.)
2,207
2,084
1,965
2,000 1,769
1,576 1,620 1,633
1,503
1,198 1,313
1,000
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Source: Pharmaprojects® | Informa, 2021 16Global drug development by phase, 2021
Other* 10%
Phase III 6%
Phase II 15%
Preclinical 55%
Phase I 14%
*Launched and in development (7%), Pre-registered (1%), Registered (1%) and Suspended & N/A (1%)
Source: Pharmaprojects® | Informa, 2021 17Global clinical drug development phase trends, 2007-2021
152%
12000
+182% 10738
10000
8000
Drug Count
6000
3803
+152% +102%
4000
2676 2747
2000 1360
+131%
1060
1029
446
0
Preclinical Phase I Phase II Phase III
2007-2021 per phase
Source: Pharmaprojects® | Informa, 2021 18Distribution of R&D companies by HQ country/region, 2021
Germany 2%
France 3%
C & S America/Africa 1%
Japan 3%
Canada 4%
UK 5%
China 9%
USA 46%
Rest of Asia Pacific 13%
Rest of Europe 14%
Source: Pharmaprojects® | Informa, 2021 19Share of pipeline contributed by top 10 companies, top 25 companies and
companies with just 1 or 2 two drugs, 2011-2021
Top 10 Top 25 Cos with 1 or 2 drugs
25
23
21
19.61 19.6 19.74
19.26 19.38 19.36
18.32 18.96 18.7
% of total pipeline
19 18.33 18.33
17 16.48
17.9 17.93 15.72
14.77 14.89
15
13.38 13.5
13 12.14 11.95
11.49 11.42
11.01
11 10
9.6 9.47 9.36
9 8.22
7.21
7 6.45
5.4 5.27
5
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Source: Pharmaprojects® | Informa, 2021 20Nanoform Business Model
21Simplified value chain
High level overview of Nanoform’s value chain and business model
Bulk
API
Launch of new drugs,
improving existing drugs &
reducing clinical attrition
Clients Revenue
➢ Global large pharma Nanoformed ➢ Fixed fee’s per project
➢ Mid-sized and specialty
pharma API ➢ Royalty as a % based on
drug sales or supply price
per kg
➢ Biotech
➢ Nanoform nanoforms APIs for the pharma and biotech industry using its patented CESS ® technology
API = Active Pharmaceutical Ingredient
CESS® = Controlled Expansion of Supercritical Solutions 22
GMP = Good Manufacturing PracticeRevenue drivers and industry attrition rates
Nanoform pre-clinical and clinical revenue drivers Global Pharmaceutical industry’s pre-clinical and clinical success rates
NME Biologic Non-NME 1)
Non-GMP GMP
100%
90%
88%
> Attrition between previous 90%
and current phase
78%
80%
> Price per phase per API 74%
70%
> Total # of active > Time lag between 70% 66%
Proof of customers previous and current 61%
Phase I,
Concept phase 60% 57%
> # of APIs per customer II & III
(PoC) > # of customers with
> Price per PoC per API 48% 49%
505(b)(2) strategy 50%
> Proportion of new drug
40% 37%
candidates and 505(b)(2) 34%
APIs
30% 25% 26%
23%
20%
> # of drugs on the market
10% 4%
using CESS® 2%
> License fee & royalty level 0%
> Attrition between PoC and per drug Pre-clinical to Phase I to Phase II to Phase III to NDA/BLA to Initial phase
Proof of PoP Drugs on > Net revenues per drug Phase I 2) Phase II Phase III NDA/BLA Approval to Approval
Process > Price per PoP per API the > Time lag Phase II and
(PoP) > Time lag between PoC and market market (505b2)
PoP > Time lag Phase III and
Timeline
market (years) Pre-clinical Phase I Phase II Phase III Approval Total
> Speed of uptake on New drugs ~1-4 ~2 ~2 ~3-4 ~1 ~9-13
market
Existing drugs - Clinical development for 505(b)(2) ~2-5 ~1 ~3-6
Source: Company information; Takebe, Imai & Ono (2018), Clinical and Translational Science (11) (Pre-clinical to Phase I); Biotechnology Innovation Organization,
Biomedtracker and Amplion, Clinical Development Success Rates 2006-2015 (Clinical success rates); Kaur, Sharma & Sharma (2014), Journal of Drug Delivery and
& Therapeutics (4) (Timeline); The Pharmaceutical Journal, Drug Development: The Journey of a Medicine from Lab to Shelf (Timeline); Camargo Pharmaceutical 23
Services, Understanding the 505(b)(2) Approval Pathway (Timeline); 1) Non-NMEs often use 505(b)(2) pathway to gain FDA approval, source: Biotechnology
Innovation Organization, Biomedtracker and Amplion 2) Academic drug discovery, NME consisting only of small moleculesNanoform - Attractive revenue model
Predictable revenue streams through capitalizing the entire pharmaceuticals value chain
Phase Proof of Concept / Proof of Process Phase I – III trials Drugs on the market
Certification Non-GMP GMP GMP
➢ Proof of concept study - assessment of the ➢ API for clinical trials are manufactured in ➢ Drugs that have passed the trials and
possibility to nanoform a specific API Nanoforms GMP facility reached commercialization
➢ Proof of process study - definition of ➢ Supply of material for customers’ Phase I, ➢ In practice, if a company has taken its drug
parameters to establish the optimal process II and III trials through Phase II trials, it is difficult to
Description and controls for a specific API switch manufacturer
➢ Nanoform gets paid regardless of the
outcome of the trials
➢ Significant potential from patent extension
(505b2 projects) of drugs already on the
market offering near-term revenues
Fixed fee per project Fixed fee per project Royalty as a % based on drug sales or
Revenue
Estimated project fee of EUR 50-500k Estimated project fee of EUR 0.5-10m supply price per kg
model per API per project per API per phase Estimated royalty fee of 1-20%
➢ Attractive business model with diversified risk profile due to not having to carry the cost & risk of drug development or being
dependent on a single drug
24Highlights
KPI’s and Financials
Near and mid-term business targets
25Nanoform highlights year-to-date (2021)
Letter of intent for the development,
7 new clients
Strong manufacturing, and commercialization
3 new collaborations
clinical results of a by nanoforming improved version of a
1 new co-development
current blockbuster drug signed
4 new non-GMP lines
Q2 gross margin jumped to 95% 8 new customer PoC
commissioned in 1H
as revenue grew by 185 % p.a. projects started in 1H21
taking total to 12
New raised 'mid-term
Headcount increased
STARMAP® v2.0 business targets for 2025’
from 74 to 106 during 1H
launched announced in conjunction with
(37 PhD’s and 25 nationalities)
CMD June 4, 2021
Capital raise for Biologics
2 'near-term business Commercial team expanded
Strong balance sheet
targets achieved' in US and Europe
(€88m cash, no debt)
PoC = Proof of Concept
26
GMP = Good Manufacturing Practice
CMD = Capital Markets Day2021 YTD Key milestones
Nanoform set a new near-term business target for 2021: “At least 12
March Dr Chris Worrall appointed VP Business Development US (San Diego)
Jan new non-GMP customer projects and at least one new GMP customer
project in 2021”
Near-term business target “At least 3 new non-GMP lines in 2021”
March
Jan Nanoform’s clinical study indicates positive interim results achieved in Q1
Nanoform and Aprecia collaborate to advance 3D printed
Herantis Pharma signed as a client for Biologics Proof of Concept April
Nanomedicines
Feb projects and near-term target “First commercial Biologics PoC project
signed in 2021” achieved
Nanoform’s final clinical results (Unicorn study) confirm value
May
proposition to the pharma industry
Feb East Coast US Biotech client signed
Nanoform and a US listed metabolic pharmaceutical company
May collaboration signed
Feb Additional positive interim results from Nanoform’s Clinical Study
May Nanoform and Celanese explore ways to enhance drug delivery
Feb Dr Jamie Unwin appointed Commercial Insights Officer (Oxford)
May US biotech client signed
Nanoform sets a new near-term business target: “At least 3 new non-
Feb
GMP lines in 2021 and 2 new GMP lines in 2022”
June Nanoform raised its mid-term business targets for 2025
Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of
March
Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates
Letter of intent signed with a European headquartered international
June company for the development, manufacturing, and commercialization
March European biotech client signed of a by nanoforming improved version of a current blockbuster drug
Nanoform launches next-generation STARMAP® v2.0, the AI-based July Global major pharma client signed
March
drug candidate selection tool for CESS®
March Nanoform raised additional funds for accelerated growth July Master Services Agreement signed with Boehringer Ingelheim
27Clients, Collaborations and Co-developments
Client announced 2019 Nanoform targets to achieve scale in APIs
Client announced 2020 1 Global large pharma
UK Tier 2 – Mid-sized
respiratory
and specialty
Client announced 2021
biotech
pharma and biotech ✓ Financially stable organizations
✓ Broad pipeline of APIs in development
UK
Mid-sized and specialty pharma
Collaboration
announced 2021
US Major
Pharma
biotech
2 and biotech companies
Orion
Tier 1 – Global West
Co-development
large pharma Coast
US ✓ Ability to add more significant value
announced 2021
Astra
Zeneca
Global
Major
biotech
✓ Fast supplier approval process
Pharma
Technology added value to clients and collaborations
Herantis European
Pharma International
company
Global
Major
Pharma
Global
Major
Boehringer ✓ Enabling new products
Ingelheim
Pharma (MSA)
East Coast US
US Biotech Celanese biotech
Corporation
✓ Addressing solubility & bioavailability challenges
Nacuity
Pharmac. US listed
metabolic
European
Biotech Aprecia
pharma
✓ Broadening & deepening the customer’s pipeline
28Nanoform Q2 2021 KPI’s
Financial KPI’s
Financial KPIs Operational KPI’s
EUR thousand 4-6/2021 4-6/2020 1-6/2021 1-6/2020 1-12/2020 1-12/2019 4-6/2021 4-6/2020 1-6/2021 1-6/2020 1-12/2020 1-12/2019
Revenue 546 191 824 342 687 49
Number of new projects
started during the period
Gross profit 518 159 761 262 497 -323
Gross margin 95% 83% 92% 77% 72% neg.
Non-GMP 2 1 8 5 10 2
EBITDA -4,358 -6,348 -8,283 -10,485 -18,196 -6,900
GMP 0 0 0 0 0 0
Operating loss -4,841 -6,622 -9,203 -10,987 -19,423 -7,344
Loss for the period -5,340 -6,758 -9,610 -11,345 -19,441 -7,554
Basic EPS (EUR) -0.07 -0.14 -0.14 -0.23 -0.35 -0.19 Number of lines (end of
the period)
Net debt -82,563 -69,751 -82,563 -69,751 -54,156 -3,640
Non-GMP 12 7 12 7 8 4
Net debt excluding lease
-88,120 -74,101 -88,120 -74,101 -59,977 -6,626
liabilities
GMP 1 1 1 1 1 0
Investments in property,
-1,798 -514 -2,658 -838 -2,336 -1,804
plant and equipment
Operative free cash flow -6,156 -6,863 -10,941 -11,322 -20,532 -8,704
Cash and cash equivalents Number of employees (end
88,120 75,155 88,120 75,155 61,025 7,303 106 55 106 55 74 43
(end of period) of the period)Nanoform Q2 2021 Income Statement
Consolidated statement
Consolidated statement of comprehensive
of comprehensive income income 1-6/2021 comments
EUR thousand 4-6/2021 4-6/2020 1-6/2021 1-6/2020 1-12/2020 1-12/2019
➢ Revenue stemmed from 16 different customer projects in 1H21 (7 projects in
Revenue 546 191 824 342 687 49 1H20). Revenues are recognized over the lifetime of the projects, based on
hours worked. In 1H21 revenue grew 141% compared with 1H20.
Other operating income 14 27 27 231 ➢ The gross profit and margin jumped to EUR 761 thousand and 92% in 1H21
compared with EUR 262 thousand and 77% in 1H20. The operating loss
improved to EUR -9.2m from EUR –11.0m (1H20 included 4.6m in IPO related
costs). Financial costs in Q2 includes EUR 0.3m from repayments of BF loans.
Materials and services -28 -47 -63 -107 -216 -603
Employee benefits -3,693 -4,609 -6,453 -7,551 -12,526 -4,359 ➢ Headcount increased to 106 (55 end of 2Q20).
Depreciation,
amortization and ➢ Cash position was EUR 88.1 million (EUR 75.2 million).
-483 -274 -920 -502 -1,226 -444
impairment losses
Other operating Other operating expenses
-1,183 -1,898 -2,591 -3,195 -6,168 -2,218
expenses
4-6/2021 4-6/2020 1-6/2021 1-6/2020 1-12/2020 1-12/2019
Premises expenses 31 14 52 28 106 66
Operating loss -4,841 -6,622 -9,203 -10,987 -19,423 -7,344
IT expenses 152 77 234 140 309 202
Marketing and
Total finance income and 136 55 290 137 427 312
-498 -135 -405 -358 -15 -209 communication expenses
expenses
Consultant and
272 1,124 624 1,898 2,884 858
professional fees
Loss before tax -5,339 -6,758 -9,609 -11,345 -19,438 -7,554 Travel expenses 18 8 37 65 100 269
Voluntary personnel
149 128 384 205 532 304
related expenses
Income tax -1 -1 -4
R&D expenses - external 169 430 539 614 1,357 28
Other expenses 256 63 439 107 453 180
Loss for the period -5,340 -6,758 -9,610 -11,345 -19,441 -7,554 Total 1,183 1,898 2,591 3,195 6,168 2,218
Source: Company information
30Number of non-GMP lines and started customer PoC projects
">70 new API's
20 per year"
20 Number of new Proof of Concept (PoC) Number of non-GMP manufacturing lines by
customer projects started - per quarter end of period (cumulative)
70
18
Number of new Proof of Concept (PoC) New Proof of Concept (PoC) customer
customer projetcs started - cumulative projects (FY/H1)
60
"21-28
non-
15
GMP
50 lines"
"At least
12 12 new
API’s in
40 2021"
“At least 3
10 more non-
9
30 GMP lines in
2021”
7 (11 or more
in total)
6 6 20
5 12
4 10
10 8 8
3
4
2 2 2 2 2
1 0
FY 2019 FY 2020 H1 2021 Near-term Mid-term
0 business business
Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 targets (2021) targets (2025)
GMP = Good Manufacturing Practice 31Nanoform near-term business targets (re-iterated)
Topic Target Status
GMP Approval “GMP approval expected no later than Q3 2020” Achieved - GMP certificate
awarded April 2020 ✓
Ongoing Client Intake
“For 2020, our ambition is to accelerate our growth by
winning more new customers than in 2019”
Achieved – 4 new customers
by July 2020 ✓
First GMP Project “Start of first GMP project before year end 2020”
Achieved – First GMP campaign started
in October 2020 ✓
Clinical Trials “First dosing in humans in 2021”
Achieved – First dosing in humans
announced December 2020 ✓
Biologics “First commercial Biologics PoC project signed in 2021”
Achieved – First Biologics PoC
agreement signed February 2021 ✓
Non-GMP Line Capacity “At least 3 new non-GMP lines in 2021”
Achieved – 3 new non-GMP lines ready
in Q1 2021 ✓
“At least 12 new non-GMP customer projects
Customer Projects and at least one new GMP project in 2021”
New target - Jan 4
GMP Line Capacity “2 new GMP lines in 2022” New target – Feb 26
GMP = Good Manufacturing Practice 32
PoC = Proof of ConceptNanoform mid-term business targets 2025 (re-iterated)
- New raised targets were announced June 2th, 2021
35 lines
>70 of which
new APIs 7-14 are
200-250
employees
per year GMP
compliant
>90% Cash flow
gross positive
margin
API = Active Pharmaceutical Ingredient 33
GMP = Good Manufacturing PracticeA Selection of Nanoform Institutional Shareholders1
1) Latest ownerhsip data can be found at https://nanoform.com/en/ownership-structure/ 34Q&A
www.nanoform.com
San Diego - Chicago - New York - Lisbon - Oxford - Cambridge - Stockholm - Helsinki
35FURTHER ENQUIRIES CFO Albert Hæggström albert.haeggstrom@nanoform.com +358 29 370 0150 Director of Investor Relations Henri von Haartman hvh@nanoform.com +46 7686 650 11 FINANCIAL CALENDAR November 25, 2021 - Interim Report for January-September 2021 February 22, 2022 – Full Year 2021 Report
You can also read
